MIRA INFORM REPORT

 

 

Report Date :

29.05.2014

 

IDENTIFICATION DETAILS

 

Name :

DIVI’S LABORATORIES LIMITED

 

 

Registered Office :

7-1-77/E/1/303, Dharam Karan Road, Amarpret, Hyderabad-500016, Andhra Pradesh

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

12.10.1990

 

 

Com. Reg. No.:

01-011854

 

 

Capital Investment / Paid-up Capital :

Rs.265.469 Millions

 

 

CIN No.:

[Company Identification No.]

L24110AP1990PLC011854

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

HYDD00549D

 

 

Legal Form :

A Public Limited Liability Company.  The Company’s Shares are Listed on the Stock Exchanges.

 

 

Line of Business :

The company is engaged in manufacturing and sale of active pharma ingredients and intermediates.

 

 

No. of Employees :

100 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Aa (72)

 

RATING

STATUS

PROPOSED CREDIT LINE

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

Large

 

Maximum Credit Limit :

USD 102000000

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well-established and a reputed company having fine track record. Financial position of the company seems to be sound. Fundamentals are strong and healthy. Directors are reported to be an experienced and respectable businessmen. Trade relations are reported as fair. Business is active. Payments are reported to be regular and as per commitments.

 

The company can be considered normal for business dealings at usual trade terms and conditions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – September 30, 2013

 

Country Name

Previous Rating

(30.06.2013)

Current Rating

(30.09.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

The current downturn provides an opportunity to push ahead with reforms to accelerate growth, says the latest India Development Update report released by the World Bank. The report says that the adverse effects of rupee depreciation are likely to be offset by the gains in the exports performance due to improved external competitiveness. Since May this year, the local currency has depreciated substantially and fell to a record level of Rs 68.85 to a dollar on August, 28.

 

A stagflation like situation appears to have arisen as inflation jumped to an eight month high of 6.46 % for the month of September. It is up from 6.10 % in August. Growth continues to be muted with factory output plunging to 0.6 % in August. Onion prices have risen nearly 300 % from last September. Vegetables cost nearly 90 % more than they did last year. Wake up to the economic contribution of slum dwellers. They contribute more than 7.5 % to the country’s gross domestic product, according to a recent study conducted in 50 top cities.

 

136000 estimated number of jobs created during the second quarter of the current financial year. 50000 estimated number of additional jobs in the field of corporate social responsibility in the coming years.

 

The International Finance Corporation expects to come out with its rupee linked bonds issue before the end of 2013 as a part of its plan to raise $ 1 billion. The Apple iPhone 5c (Rs 41900 for 16 GB variant) and 5s (Rs 53500 for 16GB variant) has been launched in India from 1st November.

 

The Land Acquisition Act to provide just and fair compensation to farmers will come into force from January 1 next year, said Rural Development Minister Jairam Ramesh. The Act replaces a 119 year old registration. The Securities and Exchange Board of India has approved the trading of currency futures on the Bombay Stock Exchange. The exchange plans to launch the currency futures platform with advanced trading technology by the end of November.

 

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

CARE

Rating

Long Term Bank Facilities = AA+

Rating Explanation

High credit quality and low credit risk

Date

07.10.2013

 

 

Rating Agency Name

CARE

Rating

Short Term Bank Facilities = A1+

Rating Explanation

Very strong degree of safety and lowest credit risk

Date

07.10.2013

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

INFORMATION DENIED

 

Management Non-Cooperative (Tel No.: 91-40-23731318)

 

 

LOCATIONS

 

Registered Office :

7-1-77/E/1/303, Dharam Karan Road, Amarpret, Hyderabad – 500016, Andhra Pradesh, India

Tel. No.:

91-40-23731318/ 23731760 / 61 / 23786300

Fax No.:

91-40-23733242 / 23786460

E-Mail :

mail@divislaboratories.com

marketing@divislaboratories.com

kiran@divislaboratories.com

chemicals@divislaboratories.com

kishore@divislaboratories.com

purchase@divislaboratories.com

nlr@divislaboratories.com

Website :

http://www.divislabs.com

http://www.divislaboratories.com

 

 

Factory 1 :

Choutuppal Unit

 

Lingojigudem Village, Choutuppal Mandal, Nalgonda – 508252, Andhra Pradesh, India

Tel. No.:

91-8694-272092, 272260

Fax No.:

91-8694-272685

 

 

Factory 2 :

100% Export Oriented Unit – Chippada / Divi’s Pharma SEZ / DSN SEZ Unit

 

Chippada Village, Bheemunipatnam Mandal, Visakhapatnam-531162, Andhra Pradesh, India

Tel. No.:

91-8922-245166

Fax No.:

91-8922-245165

 

 

R and D Centers:

Located At:

 

·         B-34, Industrial Estate, Sanathnagar, Hyderabad - 500 018, Andhra Pradesh, India

·         Lingojigudem Village, Choutuppal Mandal, Nalgonda - 508 252, Andhra Pradesh, India

·         Chippada Village, Bheemunipatnam Mandal, Visakhapatnam-531 162, Andhra Pradesh, India

 

 

DIRECTORS

 

As on 31.03.2013

 

Name :

Dr. Murali K Divi

Designation :

Chairman and Managing Director

Date of Birth / Age :

62 Years

Qualification :

M. Pharm. Ph.D.

 

 

Name :

Mr. N V Ramana

Designation :

Executive Director

Date of Birth / Age :

55 Years

Qualification :

B.Sc. (Chem)

 

 

Name :

Mr. Madhusudana Rao Divi

Designation :

Director (Projects)

Date of Birth / Age :

14.01.1944

Qualification :

Post-graduate degree in Structural Engineering from Mysore University, Karnataka

Date of Appointment :

14.10.1994

 

 

Name :

Mr. Kiran S. Divi

Designation :

President Director

Date of Birth / Age :

37 Years

Qualification :

B. Pharm.

 

 

Name :

Dr. K. Satyanarayana

Designation :

Director

 

 

Name :

Mr. S. Vasudev

Designation :

Director

 

 

Name :

Mr. G. Venkat Rao*

Designation :

Director

 

 

Name :

Prof. C. Ayyanna

Designation :

Director

 

 

Name :

Dr. G. Suresh Kumar

Designation :

Director

Date of Birth / Age :

22.01.1951

Qualification :

·         MBBS from Gandhi Medical College, Hyderabad.

·         M.S. (General Surgery) from Gulbarga University, Karnataka.

Date of Appointment :

10.03.2001

 

 

Name :

Mr. R. Ranga Rao**

Designation :

Director

Date of Birth / Age :

10.07.1951

Qualification :

Post-graduate degree in Pharmacy from College of Pharmacy, Manipal, Karnataka.

Date of Appointment :

03.11.2012

 

*Ceased to be a Director w.e.f. 03.11.2012

**Appointed as an additional Director w.e.f. 03.11.2012

 

 

KEY EXECUTIVES

 

Name :

Mr. P.V. Lakshmi Rajani

Designation :

Company Secretary

 

 

Name :

Mr. L. Kishore Babu

Designation :

Chief Financial Officer

 

 

SHAREHOLDING PATTERN

 

As on 31.03.2014

 

Names of Shareholders

No. of Shares

Percentage of Holding

(A) Shareholding of Promoter and Promoter Group

 

 

http://www.bseindia.com/include/images/clear.gif(1) Indian

 

 

http://www.bseindia.com/include/images/clear.gifIndividuals / Hindu Undivided Family

65080616

49.03

http://www.bseindia.com/include/images/clear.gifBodies Corporate

4000000

3.01

http://www.bseindia.com/include/images/clear.gifSub Total

69080616

52.04

http://www.bseindia.com/include/images/clear.gif(2) Foreign

 

 

http://www.bseindia.com/include/images/clear.gifIndividuals (Non-Residents Individuals / Foreign Individuals)

50000

0.04

http://www.bseindia.com/include/images/clear.gifSub Total

50000

0.04

Total shareholding of Promoter and Promoter Group (A)

69130616

52.08

(B) Public Shareholding

 

 

http://www.bseindia.com/include/images/clear.gif(1) Institutions

 

 

http://www.bseindia.com/include/images/clear.gifMutual Funds / UTI

15862213

11.95

http://www.bseindia.com/include/images/clear.gifFinancial Institutions / Banks

172522

0.13

http://www.bseindia.com/include/images/clear.gifForeign Institutional Investors

24163231

18.20

http://www.bseindia.com/include/images/clear.gifSub Total

40197966

30.28

http://www.bseindia.com/include/images/clear.gif(2) Non-Institutions

 

 

http://www.bseindia.com/include/images/clear.gifBodies Corporate

12234045

9.22

http://www.bseindia.com/include/images/clear.gifIndividuals

 

 

http://www.bseindia.com/images/clear.gifIndividual shareholders holding nominal share capital up to Rs.0.100 Million

8192076

6.17

http://www.bseindia.com/images/clear.gifIndividual shareholders holding nominal share capital in excess of Rs.0.100 Million

945607

0.71

http://www.bseindia.com/include/images/clear.gifAny Others (Specify)

2033980

1.53

http://www.bseindia.com/include/images/clear.gifNon Resident Indians

903780

0.68

http://www.bseindia.com/include/images/clear.gifDirectors & their Relatives & Friends

666470

0.50

http://www.bseindia.com/include/images/clear.gifTrusts

143753

0.11

http://www.bseindia.com/include/images/clear.gifClearing Members

319977

0.24

http://www.bseindia.com/include/images/clear.gifSub Total

23405708

17.63

Total Public shareholding (B)

63603674

47.92

Total (A)+(B)

132734290

100.00

(C) Shares held by Custodians and against which Depository Receipts have been issued

0

0.00

http://www.bseindia.com/include/images/clear.gif(1) Promoter and Promoter Group

0

0.00

http://www.bseindia.com/include/images/clear.gif(2) Public

0

0.00

http://www.bseindia.com/include/images/clear.gifSub Total

0

0.00

Total (A)+(B)+(C)

132734290

100.00

 

 

 

 

BUSINESS DETAILS

 

Line of Business :

The company is engaged in manufacturing and sale of active pharma ingredients and intermediates.

 

 

Products :

Product Description

ITC Code

Naproxen

2907.29.90

Dextromethorphan HBR

2942.00.90

Levetiracetam

2942.00.90

 

PRODUCTION STATUS (As on 31.03.2011)

 

Particulars

Unit

Installed Capacity

Actual Production

Active Pharma Ingredients and Intermediates

MTs

4500

2595.39

 

Note:

 

Net of captive consumption of 6421.08 MTs (Previous year 3525.88 MTs)

 

 

GENERAL INFORMATION

 

No. of Employees :

100 (Approximately)

 

 

Bankers :

·         State Bank of Hyderabad

·         State Bank of India

·         The Lakshmi Vilas Bank Limited

·         Bank of Nova Scotia

 

 

Facilities :

SECURED LOANS

31.03.2013

Rs. In Millions

31.03.2012

Rs. In Millions

Long Term Borrowings

 

 

From Banks

0.000

24.966

Less: Current maturities of long-term debt

0.000

(24.966)

Short Term Borrowings

 

 

Working Capital Loans from banks

218.803

450.620

Overdraft against Fixed Deposits from banks

86.342

51.417

Total

305.145

502.037

 

Long Term Borrowings

 

Nature of Security :

 

1.       Secured by equitable mortgage of specified immovable properties of the Company and further secured by first charge of all the movables (Save and except Book-debts) including movable machinery, machinery spares, tools and accessories present and future, subject to prior charge created and / or to be created in favour of the bankers on the stocks for working Capital Requirements.

 

2.       The above Term Loans and interest due thereon have been paid upto date and there are no continuing defaults.

 

Short Term Borrowings

 

Working Capital Loans from banks (Secured) :

 

1.       Nature of Security : Secured by hypothecation of stocks, book debts and receivables and further secured by second charge on fixed assets of the company)

2.       There are no defaults in repayment of loans and interest

3.       The above loans carry interest @ 11% to 12.50% p.a.

 

Overdraft against Fixed Deposits from banks (Secured) : 

 

1.       Nature of Security : Secured by hypothecation of Fixed Deposits of the    company

2.       There are no defaults in repayment of loans and interest

3.       The above loans carry interest @ 9.50% to 9.75% p.a.

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

P.V.R.K. Nageswara Rao and Company

Chartered Accountants

Address :

109, Metro Residency, 6-3-1247, Rajbhavan Road, Hyderabad – 500 082, Andhra Pradesh, India

 

 

Cost Auditors :

 

Name :

EVS and Associates

Cost Accountants

Address :

206, Raghava Ratna Towers, Chirag Ali Lane, Hyderabad – 500 001, Andhra Pradesh, India

 

 

Wholly Owned Subsidiary

·         Divis Laboratories (USA) Inc

·         Divi’s Laboratories EUROPE AG

 

 

Company In Which Key Management Personnel have Significant Influence :

·         Divi’s Biotech Private Limited

·         Divis Pharmaceuticals Private Limited

·         Divi’s Resorts Private Limited

·         Touchstone Equities Limited

·         Divi’s Properties Private Limited

 

 

CAPITAL STRUCTURE

 

As on 31.03.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

150000000

Equity Shares

Rs.2/- each

Rs.300.000 Millions

 

Issued Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

132734290

Equity Shares

Rs.2/- each

Rs.265.469 Millions

 

Reconciliation of the number of shares

 

Equity Shares

Number of Shares

Shares outstanding at the beginning of the year

132734290

Shares issued during the year

-

Shares outstanding at the end of the year

132734290

 

Details of equity shares held by shareholders holding more than 5% shares:

 

Name of Shareholder

Number of Shares

% holding

Promoters Group :

 

 

Dr.Murali Krishna Prasad Divi

7783500

5.86%

Satchandra Kiran Divi

23000000

17.33%

Swarnalatha Divi

7000000

2.27%

Nilima Motaparti

27000000

20.34%

Other Than Promoters Group :

 

 

Reliance Capital Trustee Company Limited

10073608

7.59%

 

Aggregate number of bonus shares issued during the period of five years immediately preceding the reporting date

 

On 2nd August 2009, the company issued 64847975 equity shares of Rs.2/- each as fully paid bonus shares by capitalization of general reserve and other free reserves.

 

Terms/rights attached to equity shares:

 

The company has only one class of equity shares having a par value of Rs.2/- per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividend in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

 

During the year ended 31st March 2013, the amount of per share dividend recognised as distribution to equity shareholders was Rs.15/-

 

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

 


FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.        EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

265.469

265.469

265.190

(b) Reserves & Surplus

25267.312

21482.487

18015.265

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

25532.781

21747.956

18280.455

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

21.004

25.569

49.212

(b) Deferred tax liabilities (Net)

865.521

672.872

549.119

(c) Other long term liabilities

0.000

62.549

96.155

(d) long-term provisions

23.909

16.462

28.178

Total Non-current Liabilities (3)

910.434

777.452

722.664

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

305.145

502.037

136.244

(b) Trade payables

1583.073

1573.114

1212.354

(c) Other current liabilities

1293.535

1346.951

1050.359

(d) Short-term provisions

2334.164

2082.140

1679.249

Total Current Liabilities (4)

5515.917

5504.242

4078.206

 

 

 

 

TOTAL

31959.132

28029.650

23081.325

 

 

 

 

II.      ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

9084.990

7381.949

5897.286

(ii) Intangible Assets

0.000

0.000

0.000

(iii) Capital work-in-progress

3034.144

1815.778

1037.158

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Expenditure during construction period pending capitalization

0.000

4.106

6.199

(c) Non-current Investments

28.161

28.161

28.161

(d) Deferred tax assets (net)

0.000

0.000

0.000

(e)  Long-term Loan and Advances

1072.705

1246.908

737.219

(f) Other Non-current assets

0.000

39.276

36.862

Total Non-Current Assets

13220.000

10516.178

7742.885

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

4078.136

4770.390

5256.382

(b) Inventories

8059.484

6509.685

5430.655

(c) Trade receivables

5589.006

5339.672

3927.801

(d) Cash and cash equivalents

346.828

218.224

127.998

(e) Short-term loans and advances

598.911

640.303

581.223

(f) Other current assets

66.767

35.198

14.381

Total Current Assets

18739.132

17513.472

15338.440

 

 

 

 

TOTAL

31959.132

28029.650

23081.325

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2013

31.03.2012

31.03.2011

 

SALES

 

 

 

 

 

Income

21288.899

18449.281

13148.695

 

 

Other Income

485.125

657.607

292.253

 

 

TOTAL                                     (A)

21774.024

19106.888

13440.948

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of Raw materials consumed

8978.981

7717.730

4866.797

 

 

Purchases of Stock-in-trade

0.943

1.006

0.000

 

 

Changes in inventories of finished goods, work-in progress and Stock-in-trade

(1003.310)

(106.566)

345.229

 

 

Employee benefits expense

1912.018

1451.562

1120.556

 

 

Research and development expenses

239.987

188.593

159.809

 

 

Other expenses

2942.835

2248.269

1609.380

 

 

TOTAL                                     (B)

13071.454

11500.594

8101.771

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

8702.570

7606.294

5339.177

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

17.765

37.432

15.165

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

8684.805

7568.862

5324.012

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

768.956

620.311

533.515

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                               (G)

7915.849

6948.551

4790.497

 

 

 

 

 

Less

TAX                                                                  (H)

1801.637

1488.858

434.836

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

6114.212

5459.693

4355.661

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

16414.995

14211.413

12146.806

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

 

Proposed Dividend

1991.014

1725.546

1325.951

 

 

Provision for Corporate Dividend Tax

338.373

279.927

215.103

 

 

Dividend of earlier year

0.000

0.549

0.000

 

 

Corporate Dividend Tax of earlier year

0.000

0.089

0.000

 

 

Amount transferred to General Reserve

1500.000

1250.000

750.000

 

BALANCE CARRIED TO THE B/S

18699.820

16414.995

14211.413

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

FOB Value of Exports

18601.633

16068.838

11811.894

 

 

Contract Research Fee

22.439

58.958

23.840

 

 

Job work charges

165.304

23.093

0.000

 

TOTAL EARNINGS

18789.376

16150.889

11835.734

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

4479.898

3486.414

2369.903

 

 

Packing Material

11.166

17.218

6.724

 

 

Lab Chemicals

20.301

11.819

6.123

 

 

Components and Spare parts

7.575

7.450

17.929

 

 

Capital goods

162.425

115.536

122.366

 

TOTAL IMPORTS

4681.365

3638.437

2523.045

 

 

 

 

 

 

Earnings Per Share (Rs.)

46.06

41.15

32.90

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

31.03.2012

31.03.2011

PAT / Total Income

(%)

28.08

28.57

32.41

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

37.18

37.66

36.43

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

86.50

93.68

81.03

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.31

0.32

0.26

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

0.01

0.02

0.01

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

3.40

3.18

3.76

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2011

31.03.2012

31.03.2013

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Share Capital

265.190

265.469

265.469

Reserves & Surplus

18015.265

21482.487

25267.312

Net worth

18280.455

21747.956

25532.781

 

 

 

 

long-term borrowings

49.212

25.569

21.004

Short term borrowings

136.244

502.037

305.145

Total borrowings

185.456

527.606

326.149

Debt/Equity ratio

0.010

0.024

0.013

 

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2011

31.03.2012

31.03.2013

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Sales

13,148.695

18,449.281

21,288.899

 

 

40.313

15.391

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2011

31.03.2012

31.03.2013

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Sales

13,148.695

18,449.281

21,288.899

Profit

4,355.661

5,459.693

6,114.212

 

33.13%

29.59%

28.72%

 

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

Yes

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

----------

22]

Litigations that the firm / promoter involved in

----------

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

----------

26]

Buyer visit details

----------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

Yes

UNSECURED LOAN:

 

Particulars

31.03.2013

Rs. In Millions

31.03.2012

Rs. In Millions

Long Term Borrowings

 

 

Deferred Payment Liabilities

 

 

Deferred Sales Tax Credit

25.569

27.424

Less: Current maturities of long-term debt

(4.565)

(1.855)

Total

21.004

25.569

 

Notes:

 

Term of Repayment:

 

Period: 14 Years

Number of Installments due: 5

Rate of Interest: Interest free

 

The above liability due thereon has been paid upto date and there are no continuing defaults.

 

        

INDUSTRY OUTLOOK

 

Pharmaceutical market research firm, IMS Health forecast that the global spending on medicines annually will grow from about $956 bn in 2011 to nearly $1.2 trillion by the year 2016, as the pharmerging markets, biologics and generics contribute a greater shape of spending. Developed markets will decline to 57% of global spending due to patent expiries, slower brand spending growth and increased cost containment actions by payers. In next five years, pharmerging markets share of spending will increase by 10% points to 30% of global spending.

 

IMS Health predicts that North and South America, Europe and Japan will continue to account for a full 85% of the Global pharma market well into the 21st century.

 

The generic drug market is gaining increasing ground over branded pharmaceuticals, with the FDA reporting that generics account for more than 70% of prescription drugs in the US, according to BCC Research report. The global generic drug market should grow at a CAGR of 15% over 5 years. While US market for generic drugs is forecast to show more than 10% CAGR, reaching $54, Japan is likely to see over 12% growth to exceed $9.5 billion in 2014.

 

With strong presence both within the patented and generic active ingredient segments, your company will continue to support its customers by offering cost competitive and faster delivery structure.

 

 

FINANCIAL RESULTS

 

The company has achieved a sales growth of 15% for the year on the back of a decent growth of 41% achieved during the last year.

 

They made a provision of Rs.1609.000 Millions towards Income tax this year (including MAT credit utilization of Rs.79.000 Millions). Provision for last year amounted to Rs.1365.100 Millions including a MAT credit utilization of Rs.3.68 Millions. An amount of Rs.192.600 Millions has been provided towards Deferred Tax Liability during the year as against Rs.123.800 Millions during the previous year.

 

PAT amounted to Rs.6114.200 Millions for the year, reflecting a growth of 12%. Earnings Per Share of Rs.2/- each works out to Rs.460.600 for the year as against Rs.411.500 last year.

 

 

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2014

 

 (Rs. In Millions)

Sr.

No.

Particular

Quarter Ended

Year Ended

 

 

31.03.2014

31.12.2013

31.03.2014

 

 

audited

unaudited

audited

 

 

 

 

 

1.

Net Sales/Income from Operations

7380.100

6874.100

25071.800

 

Other Operating Income

25.900

18.600

67.900

 

Total Income From Operations (Net)

7406.000

6892.700

25139.700

 

 

 

 

 

2.

Expenditure

 

 

 

 

Cost of materials consumed

2217.800

2447.300

10318.900

 

Purchase of stock in trade

0.000

0.000

0.000

 

Changes in inventories of finished goods, work in progress and stock in trade

824.700

115.100

(1137.500)

 

Employee benefits expenses

591.500

571.000

2254.300

 

Depreciation and amortization expenses

253.900

232.700

920.600

 

Other expenses

1153.800

881.400

3515.400

 

Total Expenses

5041.700

4247.500

15871.700

 

 

 

 

 

3.

Profit From Operations before Other Income, Interest and Exceptional Items (1-2)

2364.300

2645.200

9268.000

 

 

 

 

 

4.

Other Income

93.800

79.100

839.000

 

 

 

 

 

5.

Profit Before Interest and Exceptional Items (3+4)

2458.100

2724.300

10107.000

 

 

 

 

 

6.

Finance Cost

9.100

3.500

20.600

 

 

 

 

 

7.

Profit After Interest but before Exceptional Items (5-6)

2449.000

2720.800

10086.400

 

 

 

 

 

8.

Exceptional Items

0.000

0.000

0.000

 

 

 

 

 

9.

Profit from Ordinary Activities before Tax (7+8)

2449.000

2720.800

10086.400

 

 

 

 

 

10.

Tax Expense

518.400

530.600

2169.200

 

 

 

 

 

11.

Net Profit from Ordinary Activities after Tax (9-10)

1930.600

2190.200

7917.200

 

 

 

 

 

12.

Extraordinary Item (net of expense)

0.000

0.000

0.000

 

 

 

 

 

13.

Net Profit for the period (11-12)

1930.600

2190.200

7917.200

 

 

 

 

 

14.

Share of profit/(loss) of Associates

0.000

0.000

0.000

 

 

 

 

 

15.

Minority interest

0.000

0.000

0.000

 

 

 

 

 

16.

Net Profit / (Loss) After tax

1930.600

2190.200

7917.200

 

 

 

 

 

 

Paid-up Equity Share Capital 

0.000

0.000

0.000

 

 

 

 

 

 

Reserve Excluding revaluation reserves

0.000

0.000

0.000

 

 

 

 

 

17.

Basic and Diluted Earning Per Share (EPS) (Rs.)-Not Annualised

 

 

 

 

a) Basic and diluted EPS before extraordinary items

14.54

16.50

59.65

 

b) Basic and diluted EPS after extraordinary items

14.54

16.50

59.65

 

 

 

 

 

17.

Public Shareholding

 

 

 

 

-Number of Shares

63603674

63556194

63603674

 

- Percentage of Shareholding

47.92%

47.88%

47.92%

 

 

 

 

 

18.

Promoters and Promoter Group Shareholding

 

 

 

 

a) Pledged/Encumbered

 

 

 

 

- Number of Shares

Nil

Nil

Nil

 

- Percentage of Shares (as a % of the Total Shareholding of promoter and promoter group)

 

Nil

 

Nil

Nil

 

- Percentage of Shares (as a % of the Total Share Capital of the Company)

 

Nil

 

Nil

Nil

 

 

 

 

 

 

b) Non Encumbered

 

 

 

 

- Number of Shares

69130616

69178096

69130616

 

- Percentage of Shares (as a % of the Total Shareholding of Promoter and Promoter Group)

100%

100%

100%

 

- Percentage of Shares (as a % of the Total Share Capital of the Company)

52.08%

52.12%

52.08%

 

Investor complaints

Quarter Ended  31.03.2014

pending at the beginning of the quarter

Nil

received during the quarter

28

disposed of during the quarter

28

unresolved at the end of the quarter

Nil

                                                                                                                                          

 

STATEMENTS ASSETS AND LIABILITIES

 

PARTICULARS

31.03.2014

 

EQUITY AND LIABILITIES

 

Shareholders' funds

 

 Share Capital

265.500

 Reserves & Surplus

30078.700

Sub total- Shareholders' funds

30344.200

Non-current liabilities

 

Long-term borrowings

15.500

Deferred tax liabilities (Net)

1216.700

Other long term liabilities

0.000

Long-term provisions

31.800

   Sub total-Non-Current Liabilities

1264.000

Current liabilities

 

Short term borrowings

163.200

Trade payables

1486.900

Other current liabilities

1465.500

Short-term provisions

3115.800

Sub total-Current Liabilities

6231.400

TOTAL EQUITY AND LIABILITIES

37839.600

 

 

ASSETS

 

Non-current assets

 

Fixed assets

 

Fixed Assets

13660.900

Goodwill on consolidation

0.000

Non-current Investments

28.200

Deferred tax assets (net)

0.000

 Long-term Loan and Advances

1190.200

Other Non-current assets

0.000

Sub total-Non-Current Assets

14879.300

Current assets

 

Investment

5018.800

Inventories

8932.700

Trade receivables

7916.300

Cash and cash equivalents

357.700

Short-term loans and advances

673.700

Other current assets

61.100

Sub total-Current Assets

22960.300

TOTAL- ASSETS

37839.600

 

 

 

Note :

1.       Ther above audited results for the quarter and year ended 31.03.2014 as reviewed  by the Audit Committee, were considered and approved by the Board of Director as its Meeting held on 24.05.2014.

2.       The company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and Intermediates. Accordingly there are no reportable segment as per the Accounting Standard 17 noticed under the companies act, 1956.

3.       While there was a forex gain for the  year

 

Particulars

Quarter Ended

Year  Ended

 

31.03.2014

31.12.2013

31.03.2014

 

Audited

Unaudited

Audited

Forex Gain / (Loss)

(180.023)

(53.404)

504.179

 

Forex gain has been included in Other Income and forex loss has been included in Other Expenses.

 

4.       Figures for the previous year/periods have also been regrouped or recasted, wherever necessary to confirm to current year’s classification.

5.        Figures for the last quarter an=re balancing figure between audited figure inrespect of the full financial year up to 31.03.2014 and the unaudited published year to date figures up to 31.12.2013, being the date of the third quarter of the financial year which was subject to limit review.

 

 

INDEX OF CHARGE:

 

Sr. No.

Charge ID

Date of Charge Creation/Modification

Charge amount secured

Charge Holder

Address

Service Request Number (SRN)

1

10024113

28/10/2006

209,000,000.00

The Bank Of Nova Scotia

6-3-346/1, Road # 1, Banjara Hills, Hyderabad, Andhra Pradesh - 500034, India

A06138333

2

90138352

17/06/2002

150,000,000.00

UTI Bank Limited

6-3-346/1, Road # 1, Banjara Hills, Hyderabad, Andhra Pradesh - 500034, India

-

3

90138306

12/07/2002 *

100,000,000.00

UTI Bank Limited

6-3-346/1, Road # 1, Banjara Hills, Hyderabad, Andhra Pradesh - 500034, India

-

4

90138250

24/05/2001 *

50,000,000.00

Industrial Development Bank Of India (IDBI)

IDBI Tower; Wtc Complex, Cuffe Purade, Mumbai, Maharashtra - 400005, India

-

5

90138195

06/12/2000 *

50,000,000.00

Industrial Development Bank Of India

IDBI Tower; Wtc Complex, Cuffe Purade, Mumbai, Maharashtra - 400005, India

-

6

90138180

06/02/2000

50,000,000.00

Industrial Development Bank Of India

IDBI Tower; Wtc Complex, Cuffe Purade, Mumbai, Maharashtra - 400005, India

-

7

90138171

16/12/2000 *

40,000,000.00

IDBI BANK LIMITED

Mahavir House, Basheer Bagh Square, Hyderabad, Andhra Pradesh - 500029, India

-

8

90138083

06/10/1999 *

630,000,000.00

State Bank of Hyderabad

IFB; Panjagutta, Hyderabad, Andhra Pradesh - 500082, India

-

9

90137956

08/12/1998 *

672,200,000.00

State Bank of Hyderabad

IFB; Panjagutta, Hyderabad, Andhra Pradesh - 500082, India

-

10

90136781

17/10/1996 *

552,400,000.00

State Bank of Hyderabad

IFB; Panjagutta, Hyderabad, Andhra Pradesh - 500082, India

-

11

90137918

19/11/2003 *

552,400,000.00

State Bank of Hyderabad

IFB; Panjagutta, Hyderabad, Andhra Pradesh - 500082, India

-

12

90137910

03/10/1996 *

102,600,000.00

The Lakshmi Vilas Bank Limited

Kukatpally Branch, Hyderabad, Andhra Pradesh, India

-

13

90137909

01/10/1996 *

341,800,000.00

State Bank of Hyderabad

Industrial Finance Branch, Panjagutta, Hyderabad,
Andhra Pradesh - 500482, India

-

14

90137905

17/10/1996 *

70,000,000.00

Industrial Development Bank Of India

IDBI Tower, Cuffe Parade, Mumbai, Maharashtra - 400005, India

-

15

90137843

24/03/1997 *

425,000,000.00

State Bank of Hyderabad

IFB; Panjagutta, Hyderabad, Andhra Pradesh - 500082, India

-

16

90137810

20/04/2006 *

37,500,000.00

The Lakshmi Vilas Bank Limited

Kukatpally, Hyderabad, Andhra Pradesh - 500872, India

-

17

90137808

13/11/2006 *

886,000,000.00

STATE BANK OF INDIA

Overseas Branch, 5-9-300, Abids, Hyderabad, Andhra Pradesh - 500001, India

-

18

90137793

05/01/1996 *

50,000,000.00

Industrial Reconstruction Bank Of India

19; Netaji Subhas Road, Culcutta, West Bengal - 700001, India

-

19

90137772

20/08/2001 *

220,000,000.00

State Bank of Hyderabad

IFB Panjagutta, Hyderabad, Andhra Pradesh - 500082, India

-

20

90137762

24/11/2006 *

1,095,000,000.00

State Bank Of Hyderabad

Industrial Finance Branch, "Topaz" Building, Amru Tha Hills, Punjagutta, Hyderabad, Andhra Pradesh- 500082, India

-

21

90137748

20/04/2006 *

132,000,000.00

State Bank of Hyderabad

Industrial Finance Branch, "Topaz" Building, Amru Tha Hills, Punjagutta, Hyderabad, Andhra Pradesh- 500082, India

-

22

90137718

14/11/1995 *

219,500,000.00

Industrial Development Bank Of India

Idbi Tower, Cuffe Purade, Mumbai, Maharashtra - 400005, India

-

23

90137702

31/03/2005 *

37,500,000.00

The Lakshmi Vilas Bank Limited

Kutapally, Hyderabad, Andhra Pradesh - 500872, India

-

 

 

FIXED ASSETS:

 

·         Land and Development

·        Buildings

·        Plant and Machinery

·        Laboratory Equipment

·        Furniture and Fixtures

·        Data Processing Equipment

·        Vehicles

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.59.08

UK Pound

1

Rs.99.20

Euro

1

Rs.80.53

 

 

INFORMATION DETAILS

 

Information Gathered by :

HTL

 

 

Analysis Done by  :

DIV

 

 

Report Prepared by :

SNT

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

8

PAID-UP CAPITAL

1~10

8

OPERATING SCALE

1~10

8

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

8

--PROFITABILIRY

1~10

8

--LIQUIDITY

1~10

8

--LEVERAGE

1~10

8

--RESERVES

1~10

8

--CREDIT LINES

1~10

8

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

YES

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

 

 

 

TOTAL

 

72

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NB

NEW BUSINESS

 

 

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.